18-methoxycoronaridine (18-MC) is a synthetic iboga alkaloid congener developed by researchers at Albany Medical College as an alternative to ibogaine. In animal studies, 18-MC attenuated self-administration and withdrawal symptoms of several drugs including cocaine, morphine, alcohol, methamphetamine, and nicotine without the tremors or toxicity seen with ibogaine. Its effects were longer lasting than ibogaine and it showed promise for treating addiction. The primary mechanism is thought to be decreasing dopamine levels in the nucleus accumbens.